Tariq Alyamani
Nephrology · Tulsa, OKNPI 1255941589
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.9% of the total across 86 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 17.4% — the pattern of someone who eats at a lot of different presentations.
Across 86 payments — averaging $31.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$471
- Travere Therapeutics, Inc.$448
- Bayer$293
- Johnson & Johnson$250
- AstraZeneca$235
- Pharmacosmos Therapeutics Inc.$153
- plus $853 from 17 others
What the payments were for
- Food & beverage$2,701100%
- Education$20%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 21 | $471 |
| Travere Therapeutics, Inc. | 19 | $448 |
| Bayer | 7 | $293 |
| Johnson & Johnson | 2 | $250 |
| AstraZeneca(2 entities) | 6 | $235 |
| Pharmacosmos Therapeutics Inc. | 3 | $153 |
| GSK | 1 | $125 |
| Idorsia Pharmaceuticals US Inc | 1 | $122 |
| Calliditas Therapeutics US Inc. | 5 | $121 |
| Otsuka America Pharmaceutical, Inc. | 4 | $95 |
| Lilly USA, LLC | 3 | $57 |
| Shield Therapeutics Inc | 1 | $51 |
| Vifor Pharma, Inc. | 2 | $46 |
| Novo Nordisk | 2 | $41 |
| Mallinckrodt Hospital Products Inc. | 1 | $28 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $25 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $25 |
| Novartis | 1 | $23 |
| Fresenius USA Marketing, Inc. | 1 | $19 |
| Akebia Therapeutics Inc | 1 | $19 |
| ANI Pharmaceuticals, Inc. | 1 | $18 |
| Scpharmaceuticals Inc. | 1 | $18 |
| OPKO Pharmaceuticals, LLC | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,703 in reported general payments places this provider in the 55th percentile of 106 nephrology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Furosemide | 12 | $48 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Tulsa
- Sunil AgrawalTulsa$40K
- Pranay KathuriaTulsa$21K
- Kevin FuTulsa$14K
- Diptesh GuptaTulsa$13K
- Janet RussellTulsa$12K
- Bobby MuthalalyTulsa$12K
- Narottam RegmiTulsa$12K
- Alpana PasrichaTulsa$9K
- Reza AzadiTulsa$9K
- Christine WilsonTulsa$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.